NexgenRx（NEGX.F）株式概要NexgenRx Inc.は、カナダの顧客が引き受けた医療給付プランの受益者のために、医薬品、歯科、その他の拡大医療請求の管理、裁定、支払いを行う。 詳細NEGX.F ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績4/6財務の健全性6/6配当金2/6報酬過去1年間で収益は154.2%増加しました リスク分析株式の流動性は非常に低い 過去5年間で収益は年間40.8%減少しました。 4%の配当は利益で十分にカバーされていない 意味のある時価総額がありません ( $27M )すべてのリスクチェックを見るNEGX.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.2718.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-697k30m2016201920222025202620282031Revenue CA$30.2mEarnings CA$1.8mAdvancedSet Fair ValueView all narrativesNexgenRx Inc. 競合他社Huize HoldingSymbol: NasdaqGM:HUIZMarket cap: US$17.2mMarketing AllianceSymbol: OTCPK:MAALMarket cap: US$8.7mHealth In TechSymbol: NasdaqCM:HITMarket cap: US$99.6mSelectQuoteSymbol: NYSE:SLQTMarket cap: US$211.6m価格と性能株価の高値、安値、推移の概要NexgenRx過去の株価現在の株価CA$0.2752週高値CA$0.2852週安値CA$0.27ベータ0.451ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化10.79%5年間の変化-27.24%IPOからの変化42.11%最新ニュースお知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.お知らせ • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.お知らせ • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.最新情報をもっと見るRecent updatesお知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.お知らせ • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.お知らせ • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.お知らせ • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.お知らせ • Oct 01NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of DirectorsNexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively.お知らせ • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.お知らせ • May 18Charles Burns Tenders Resignation as Director of NexgenRx IncNexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024.お知らせ • Apr 03NexgenRx Inc., Annual General Meeting, May 16, 2024NexgenRx Inc., Annual General Meeting, May 16, 2024.お知らせ • Dec 30NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of DirectorsNEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour.お知らせ • Dec 21NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023.お知らせ • Jun 16NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.お知らせ • May 19NexgenRx Inc. Appoints Dave Bennett as New DirectorNexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews.株主還元NEGX.FUS InsuranceUS 市場7D0%-1.3%2.1%1Yn/a-10.0%30.6%株主還元を見る業界別リターン: NEGX.FがUS Insurance業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: NEGX.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is NEGX.F's price volatile compared to industry and market?NEGX.F volatilityNEGX.F Average Weekly Movementn/aInsurance Industry Average Movement4.4%Market Average Movement7.2%10% most volatile stocks in US Market16.1%10% least volatile stocks in US Market3.2%安定した株価: NEGX.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のNEGX.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2003n/aRon Louckswww.nexgenrx.comNexgenRx Inc.は、カナダの顧客が引き受けた医療給付プランの受益者のために、医薬品、歯科、その他の拡大医療請求の管理、裁定、支払いを行う。NexSysクレーム管理、NexAdminプラン管理、NexPSPAssist患者サポートプログラムを提供。付帯サービスも提供している。TNexgenRx Inc.は2003年に設立され、カナダのトロントに本社を置いている。もっと見るNexgenRx Inc. 基礎のまとめNexgenRx の収益と売上を時価総額と比較するとどうか。NEGX.F 基礎統計学時価総額US$19.49m収益（TTM）US$773.84k売上高(TTM)US$13.11m25.2xPER（株価収益率1.5xP/SレシオNEGX.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NEGX.F 損益計算書（TTM）収益CA$17.93m売上原価CA$3.00m売上総利益CA$14.93mその他の費用CA$13.88m収益CA$1.06m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.015グロス・マージン83.28%純利益率5.90%有利子負債／自己資本比率0%NEGX.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.0%現在の配当利回り101%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/09 11:05終値2026/03/23 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NexgenRx Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.
お知らせ • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.
お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.
お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.
お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.
お知らせ • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.
お知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.
お知らせ • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.
お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.
お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.
お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.
お知らせ • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.
お知らせ • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.
お知らせ • Oct 01NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of DirectorsNexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively.
お知らせ • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.
お知らせ • May 18Charles Burns Tenders Resignation as Director of NexgenRx IncNexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024.
お知らせ • Apr 03NexgenRx Inc., Annual General Meeting, May 16, 2024NexgenRx Inc., Annual General Meeting, May 16, 2024.
お知らせ • Dec 30NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of DirectorsNEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour.
お知らせ • Dec 21NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023.
お知らせ • Jun 16NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.
お知らせ • May 19NexgenRx Inc. Appoints Dave Bennett as New DirectorNexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews.
